GlassScriptPhysician profile
Luke Curtis Cunningham
NPI 1649590134
$69,640.77
in general payments reported to CMS, 2019-2025
24 companies · $12K in 2025
The $12K reported for 2025 was more than what 79% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $1,891 · 2021: $11K · 2022: $22K · 2023: $11K · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,950 · Food and Beverage: $4,775 · Travel and Lodging: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,368.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,950.00 |
| Food and Beverage | $4,775.24 |
| Travel and Lodging | $740.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37,421.93 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Abbott Laboratories | $27,886.13 | 2019-2025 | Cardiomems, 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $973.08 | 2019-2025 | |
| Abiomed | $635.35 | 2019-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $512.76 | 2019-2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $499.25 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $465.08 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $244.66 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $176.87 | 2021-2025 | Verquvo |
| Paragonix Technologies, INC. | $162.48 | 2022 | |
| Kestra Medical Technology Services, INC. | $157.97 | 2022-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $155.61 | 2022-2024 | Optimizer, Optimizer |
| Atricure, INC. | $115.61 | 2023 | |
| Cvrx, INC. | $40.01 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $39.65 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eurofins Viracor, LLC | $25.39 | 2020 | |
| Boston Scientific Corporation | $24.44 | 2025 | General - Therapies |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.01 | 2021 | |
| Chiesi USA, INC. | $14.74 | 2019 | |
| Scpharmaceuticals INC. | $14.08 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $14.00 | 2022 | |
| Inari Medical, INC. | $13.25 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.